Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $11
Benzinga Newsdesk 21 minutes ago
Analyst RatingsNewsPrice Target
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.